[Proton pump inhibitors in peptic ulcer bleeding]

Area of Science:

• Gastroenterology
• Pharmacology

Background:

• Peptic ulcer bleeding (PUB) management often involves proton pump inhibitors (PPIs).
• Previous reviews suggest varying PPI dosage regimens for PUB treatment.
• High-dose PPI therapy involves a cumulative dose > 600 mg over 72 hours.

Purpose of the Study:

• To evaluate the efficacy of different PPI treatment regimens in managing peptic ulcer bleeding.
• To assess whether high-dose PPI therapy offers improved outcomes compared to lower doses in PUB.
• To analyze the quality of existing evidence regarding PPI dosing for PUB.

Main Methods:

• Systematic review and meta-analysis of studies on PPI treatment for PUB.
• Evaluation of study methodologies, including risk of bias and blinding.
• Analysis of event rates and clinical outcomes based on PPI dosage.

Main Results:

• Current evidence does not strongly support high-dose PPIs (> 600 mg/72h) over lower doses for improved PUB outcomes.
• Existing studies exhibit significant limitations: high risk of bias, inadequate blinding, and low event rates.
• Data are insufficient to definitively conclude that lower PPI doses are as effective as high-dose treatment.

Conclusions:

• High-dose PPI treatment is recommended for patients with serious PUB, particularly those undergoing endoscopic therapy.
• Further high-quality research is needed to clarify optimal PPI dosing strategies for PUB.
• Current recommendations, including those in Denmark, favor high-dose PPI use in specific PUB scenarios.